Literature DB >> 9305407

Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans.

L H Overby1, G C Carver, R M Philpot.   

Abstract

Variable amounts of flavin-containing monooxygenase isoforms 3 and 5 (FMO3 and FMO5) are present in microsomal preparations from adult, male, human liver. Quantitation with monospecific antibodies and recombinant isoforms as standards showed levels of FMO3 and of FMO5 that ranged from 12.5 to 117 and 3.5 to 34 pmol/mg microsomal protein, respectively. The concentration of FMO3 was greater than that of FMO5 in all samples, but the ratio of FMO3 to FMO5 varied from 2:1 to 10:1. Human hepatic microsomal samples also showed variable activities for the S-oxidation of methimazole. This activity was associated totally with FMO3; no participation of FMO5 was apparent. This conclusion was supported by several lines of evidence: first, the catalytic efficiency of FMO3 with methimazole was found to be approximately 5000 times greater than that of FMO5; second, the rate of metabolism showed a direct, quantitative relationship with FMO3 content; third, the plot of the relationship between metabolism and FMO3 content extrapolated close to the origin. A second reaction, the N-oxidation of ranitidine, exhibited a much higher Km with recombinant FMO3 than did methimazole (2 mM vs. 35 microM). However, a direct relationship between this reaction and FMO3 content in human hepatic microsomal preparations was also apparent. This result shows that even with a high Km substrate, FMO3-catalyzed metabolism can account for the majority of the product formation with some drugs. Our findings demonstrate that the contribution of FMO isoforms to human hepatic drug metabolism can be assessed quantitatively on the basis of the characteristics of the enzymes expressed in Escherichia coli.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9305407     DOI: 10.1016/s0009-2797(97)00055-0

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  22 in total

1.  Effect of pregnancy on a measure of FMO3 activity.

Authors:  Janne Hukkanen; Delia Dempsey; Peyton Jacob; Neal L Benowitz
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

2.  Ancestral-sequence reconstruction unveils the structural basis of function in mammalian FMOs.

Authors:  Callum R Nicoll; Gautier Bailleul; Filippo Fiorentini; María Laura Mascotti; Marco W Fraaije; Andrea Mattevi
Journal:  Nat Struct Mol Biol       Date:  2019-12-23       Impact factor: 15.369

3.  Characterization of human flavin-containing monooxygenase (FMO) 3 and FMO5 expressed as maltose-binding protein fusions.

Authors:  Robert R Reddy; Erik C Ralph; Meike S Motika; Jun Zhang; John R Cashman
Journal:  Drug Metab Dispos       Date:  2010-09-01       Impact factor: 3.922

4.  Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity.

Authors:  E Störmer; I Roots; J Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 5.  Role of reactive metabolites in the circulation in extrahepatic toxicity.

Authors:  Roy M Irving; Adnan A Elfarra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-06-11       Impact factor: 4.481

6.  Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N = 1345 young and elderly subjects.

Authors:  Derrek P Hibar; Jason L Stein; April B Ryles; Omid Kohannim; Neda Jahanshad; Sarah E Medland; Narelle K Hansell; Katie L McMahon; Greig I de Zubicaray; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Andrew J Saykin; Clifford R Jack; Michael W Weiner; Arthur W Toga; Paul M Thompson
Journal:  Brain Imaging Behav       Date:  2013-06       Impact factor: 3.978

7.  Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors.

Authors:  Satomi Nagashima; Makiko Shimizu; Hiroshi Yano; Norie Murayama; Toshio Kumai; Shinichi Kobayashi; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

8.  Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.

Authors:  A Joseph Bloom; Sharon E Murphy; Maribel Martinez; Linda B von Weymarn; Laura J Bierut; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

Review 9.  Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives.

Authors:  Irfan M Hisamuddin; Vincent W Yang
Journal:  Pharmacogenomics       Date:  2007-06       Impact factor: 2.533

10.  Overexpression of flavin-containing monooxygenase 5 predicts poor prognosis in patients with colorectal cancer.

Authors:  Tong Zhang; Ping Yang; Jianchang Wei; Wanglin Li; Junbin Zhong; Huacui Chen; Jie Cao
Journal:  Oncol Lett       Date:  2018-01-04       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.